Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia

Pediatric Hematology and Oncology

Volumn 31, Issue 2, 2014, Pages 169-177

  Sharifi, Mohamad Jafar ^a,b   Bahoush, Gholamreza ^c   Zaker, Farhad ^b   Ansari, Shahla ^c   Rafsanjani, Khadijeh Arjmandi ^c   Sharafi, Heidar ^b,d  

^a IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ABCC2; Acute lymphoblastic leukemia; Genetic polymorphism; Methotrexate; Pharmacogenetics

Indexed keywords

METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ADOLESCENT; BLOOD; CHILD; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; GENOTYPE; HUMAN; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84894467592     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.870625     Document Type: Article

References (27)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia.N Engl J Med. 2006;354:166-178
2. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination ofmethotrexate in childhood acute lymphoblastic leukemia andmalignant lymphoma. J Hum Genet. 2007;52:166-171
3. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46:52-63
4. Evans WE, CromWR, AbromowitchM, et al. Clinical pharmacodynamics of high-dosemethotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.NEngl J Med. 1986;314:471-477
5. Cronstein BN.Molecular therapeutics.Methotrexate and itsmechanism of action. Arthritis Rheum. 1996;39:1951-1960
6. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteinsMRP1 and MRP2. Cancer Res. 1999;59:2532-2535
7. Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res. 2001;61:7225-7232
8. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62:3144-3150
9. Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91:1113-1116
10. Aplenc R, Thompson J, Han P, et al.Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005;65:2482-2487
11. Huang L, Tissing WJ, de Jonge R, et al. Polymorphisms in folate-related genes: Association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22:1798-1800
12. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183-201
13. VlamingML, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are themain determinants for rapid elimination ofmethotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther. 2009;8:3350-3359
14. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457-473
15. Rau T, Erney B, Gores R, et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80:468-476
16. Laechelt S, Turrini E, Ruehmkorf A, et al. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11:25-34
17. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African-American patients with rheumatoid arthritis. J Rheumatol. 2008;35:572-579
18. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition ed. Lyon, France: IARC Press; 2008
19. Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7:56-65
20. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-riskmethotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672
21. Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14:221-225
22. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151-4157
23. ShimasakiN,MoriT,Torii C, et al. Influence ofMTHFRandRFC1polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30:347-352
24. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86:609-611
25. Sookoian S,CastanoG,BurguenoA, et al. Association of themultidrug- resistance-Associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol. 2008;48:125-132
26. Hoblinger A, Grunhage F, Sauerbruch T, et al. Association of the c.3972C>T variant of themultidrug resistance-Associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion. 2009;80:36-39
27. Haenisch S,MayK,WegnerD, et al. Influence of genetic polymorphisms on intestinal expression and rifampicin-Type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008;18:357-365